<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>Estrogen and Cancer</title>
    <meta content="L25OVAR" name="slug"/>
    <meta content="25" name="publication_day_of_month"/>
    <meta content="3" name="publication_month"/>
    <meta content="2001" name="publication_year"/>
    <meta content="Sunday" name="publication_day_of_week"/>
    <meta content="Editorial Desk" name="dsk"/>
    <meta content="14" name="print_page_number"/>
    <meta content="4" name="print_section"/>
    <meta content="6" name="print_column"/>
    <meta content="Opinion" name="online_sections"/>
    <meta content="http://www.nytimes.com/2001/03/25/opinion/L25OVAR.html" name="alternate_url"/>
    <docdata>
      <doc-id id-string="1280589"/>
      <doc.copyright holder="The New York Times" year="2001"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Cancer</classifier>
        <classifier class="indexing_service" type="descriptor">Ovaries</classifier>
        <classifier class="indexing_service" type="descriptor">Women</classifier>
        <classifier class="indexing_service" type="descriptor">Menopause</classifier>
        <classifier class="indexing_service" type="descriptor">Estrogen</classifier>
        <classifier class="indexing_service" type="descriptor">Tests and Testing</classifier>
        <org class="indexing_service">Ovarian Cancer National Alliance</org>
        <person class="indexing_service">Goldman, Patricia A</person>
        <classifier class="online_producer" type="types_of_material">Letter</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion/Opinion/Letters</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion/Opinion</classifier>
        <classifier class="online_producer" type="descriptor">Editorials</classifier>
        <classifier class="online_producer" type="general_descriptor">Estrogen</classifier>
        <classifier class="online_producer" type="general_descriptor">Menopause</classifier>
        <classifier class="online_producer" type="general_descriptor">Cancer</classifier>
        <classifier class="online_producer" type="general_descriptor">Anatomy and Physiology</classifier>
        <classifier class="online_producer" type="general_descriptor">Women</classifier>
        <classifier class="online_producer" type="general_descriptor">Tests and Testing</classifier>
        <classifier class="online_producer" type="general_descriptor">Hormones</classifier>
        <classifier class="online_producer" type="general_descriptor">Diseases and Conditions</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20010325T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9B06E1DC153CF936A15750C0A9679C8B63" item-length="184" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>Estrogen and Cancer</hl1>
      </hedline>
      <abstract>
        <p>Letter by Patricia A Goldman of Ovarian Cancer National Alliance says study of postmenopausal estrogen use and ovarian cancer demonstrates urgent need for screening tool to diagnose disease in earliest stage (S)</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>To the Editor:</p>
        <p>Much attention has been given to a recent study of the association between postmenopausal estrogen use and ovarian cancer mortality (news article, March 21). The study raises important questions that cry out for further research.</p>
      </block>
      <block class="full_text">
        <p>To the Editor:</p>
        <p>Much attention has been given to a recent study of the association between postmenopausal estrogen use and ovarian cancer mortality (news article, March 21). The study raises important questions that cry out for further research.</p>
        <p>As the study's authors point out, most of the women in the study likely used estrogen alone. Now, however, most postmenopausal women who have not had a hysterectomy are recommended a combination of estrogen and progestin, which has a protective effect against ovarian cancer. More studies are needed of the hormone therapies currently in use.</p>
        <p>The study demonstrates the urgent need for a screening tool to diagnose this disease in its earliest, most curable stage.</p>
        <p>PATRICIA A. GOLDMAN  President  Ovarian Cancer National Alliance  Washington, March 21, 2001</p>
      </block>
    </body.content>
  </body>
</nitf>
